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Abstract
Background: Chimeric antigen receptor (CAR)-based T cell therapy is in early clinical trials to target the
neuroectodermal tumor, neuroblastoma. No preclinical or clinical efficacy data are available for retinoblastoma
to date. Whereas unilateral intraocular retinoblastoma is cured by enucleation of the eye, infiltration of the
optic nerve indicates potential diffuse scattering and tumor spread leading to a major therapeutic challenge.
CAR-T cell therapy could improve the currently limited therapeutic strategies for metastasized retinoblastoma
by simultaneously killing both primary tumor and metastasizing malignant cells and by reducing
chemotherapy-related late effects.
Methods: CD171 and GD2 expression was flow cytometrically analyzed in 11 retinoblastoma cell lines. CD171
expression and T cell infiltration (CD3+) was immunohistochemically assessed in retrospectively collected
primary retinoblastomas. The efficacy of CAR-T cells targeting the CD171 and GD2 tumor-associated antigens
was preclinically tested against three antigen-expressing retinoblastoma cell lines. CAR-T cell activation and
exhaustion were assessed by cytokine release assays and flow cytometric detection of cell surface markers,
and killing ability was assessed in cytotoxic assays. CAR constructs harboring different extracellular spacer
lengths (short/long) and intracellular co-stimulatory domains (CD28/4-1BB) were compared to select the most
potent constructs.
Results: All retinoblastoma cell lines investigated expressed CD171 and GD2. CD171 was expressed in 15/30
primary retinoblastomas. Retinoblastoma cell encounter strongly activated both CD171-specific and GD2-
specific CAR-T cells. Targeting either CD171 or GD2 effectively killed all retinoblastoma cell lines examined.
Similar activation and killing ability for either target was achieved by all CAR constructs irrespective of the
length of the extracellular spacers and the co-stimulatory domain. Cell lines differentially lost tumor antigen
expression upon CAR-T cell encounter, with CD171 being completely lost by all tested cell lines and GD2
further down-regulated in cell lines expressing low GD2 levels before CAR-T cell challenge. Alternating the
CAR-T cell target in sequential challenges enhanced retinoblastoma cell killing.
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Conclusion: Both CD171 and GD2 are effective targets on human retinoblastoma cell lines, and CAR-T cell
therapy is highly effective against retinoblastoma in vitro. Targeting of two different antigens by sequential
CAR-T cell applications enhanced tumor cell killing and preempted tumor antigen loss in preclinical testing.
Keywords: Adoptive T-cell immunotherapy, Retinoblastoma, CD171, GD2, Antigen loss, Sequential CAR-T cell
therapy
Background
Children suffering from unilateral intraocular retinoblast-
oma can be cured with the enucleation of the eye without
any further treatment. However, 45% of all reported cases
encompass the heritable form of retinoblastoma, a biallelic
germline mutation of the retinoblastoma tumor suppressor
gene RB1. [1] In 80% of children with heritable disease, ret-
inoblastoma affects both eyes (bilateral) and 5% of the cases
are associated with an intracranial tumor (trilateral). [2]
Saving life is the highest goal in retinoblastoma ther-
apy followed by vision salvage. In order to salvage vision,
if reasonable, the eye is preserved in case of localized tu-
mors, which are treated with laser application cryo- or
brachytherapy and/or local intra-arterial chemotherapy.
In large tumors, initial reduction of the tumor size can
be achieved by systemic chemotherapy, which enables
subsequent local treatment options. High-dose systemic
chemotherapy with stem cell rescue is reserved for non-
responsive extraocular and/or metastastic disease. [3, 4]
Overall survival is high in western countries (> 95%).
However, due to a higher rate of secondary malignan-
cies, long-term overall survival is reduced in children
treated with eye preserving radio- and/or chemotherapy
compared with enucleation alone. [5, 6]
Retinoblastoma can disseminate through the optic
nerve into the central nervous system and through the
sclera via lymphatic or blood circulation of the orbit
bones to distant metastatic sites in the lymph nodes,
bones, bone marrow and liver. [7] In these cases, salvage
with high-dose chemotherapy is often not successful. In
addition, high-dose chemotherapy is highly aggressive,
and can create lifelong sequelae and morbidity for the
patient. [4, 7–9] Therefore, the search for more efficient
and better tolerated treatment options is warranted.
Adoptive T cell therapy might be a promising alternative.
Adoptive T cell immunotherapy, in which T lymphocytes
isolated from patients are engineered to express CD19-spe-
cific chimeric antigen receptors (CARs), has shown striking
anti-tumor effects against acute B cell leukemia and non-
Hodgkin lymphoma. [10–13] CAR-T cells combine two
striking characteristics of the immune system: the exquisite
antigen-binding specificity of a monoclonal antibody and the
potent toxicity of cytotoxic T lymphocytes. A spacer domain
connects the antigen-binding domain, commonly a single-
chain variable fragment (scFv) of a monoclonal antibody, to
the transmembrane domain followed by a T cell signaling
module. [14] Spacer length influences CAR-T cell function,
as the distance between the CAR-T cell and tumor antigen
epitope must be uniquely adjusted for optimal bridging. [15,
16] The signaling module incorporates the CD3-zeta domain
and a co-stimulatory domain, commonly either 4-1BB or
CD28, to provide signals necessary for full T cell activation.
The co-stimulatory domain used can affect CAR-T cell func-
tionality by triggering different signaling pathways. The 4-
1BB domain has been associated with increased CAR-T cell
persistence [17], but the CD28 domain has been demon-
strated to enhance CAR-T cell cytotoxicity. [18]
GD2 and CD171 may present promising targets for
CAR-T cell therapy of retinoblastoma. The GD2 gan-
glioside is expressed on the cell surface of several neu-
roectodermal tumors, including retinoblastoma. [19–22]
GD2 expression is highly restricted in nonmalignant tis-
sue with only low-level expression on peripheral nerves,
skin melanocytes, brain and osteoprogenitors. [23, 24]
Anti-GD2 monoclonal antibodies have already proven
safety and efficacy in clinical trials and are included in
the standard treatment for children with high-risk
neuroblastoma demonstrating its role as a target for im-
munotherapy. [25–27] CD171 (formerly L1CAM) plays
a crucial role during nervous system development, in-
cluding neuronal migration and axon guidance. [28] It
was recently shown to be expressed in retinoblastomas,
and expression in the Y79 and Rb1 cell lines correlated
with increased in vitro proliferation and chemoresistance
in a mouse model. [29] In most tumor entities CD171
expression is further described to be associated with
poor prognosis making it a potential target for new
treatment options like immunotherapy. [30–32] CD171
expression by normal tissue was examined by our group
and a safety study in non-human primates revealed no
on-target, off-tumor toxicity after infusion of up to 1 ×
108/kg CD171-specific CAR-T cells in non-conditioned
animals. [33] CAR-T-cell therapy could represent a new
treatment option for extraocular and/or metastasized
retinoblastoma. If successful, CAR-T cell therapy could
also be integrated with vision-preserving therapies for
children with bilateral retinoblastoma to reduce thera-
peutic toxicity and late treatment-related effects such as
secondary cancers, while preserving vision in at least one
eye.
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As a first step towards a CAR-T-cell therapy targeting
retinoblastoma, we here assessed CD171 expression in
retrospective retinoblastoma samples and investigated
the killing efficacy of CD171- and GD2-specific CAR-T
cells harboring different spacer lengths (short versus
long) and intracellular co-stimulatory domains (CD28
versus 4-1BB) in a panel of three different cell lines. Our
aim was to assess functional differences of various CAR-
T cell constructs to select the most efficient for further
preclinical testing and entry into the clinic trials.
Methods
Retinoblastoma samples and cell lines
Tumor samples and medical records were retrospectively
evaluated from 30 children diagnosed with retinoblastoma
between January 2003 and August 2013 in the Department
of Pediatric Oncology and Hematology, Charité - Universi-
tätsmedizin Berlin. Cell lines RB247C3, RB355, RB383,
RB522, RB1021 and RB3823 were kindly provided by Brenda
Gallie (Department of Ophthalmology and Vision Sciences,
Hospital for Sick Children, Toronto, Ontario, Canada). [34]
RBL13, RBL15 and RBL30 cell lines were established at the
University Hospital Essen and were obtained from the Insti-
tute of Cell Biology, University Hospital Essen. [35] Cell lines,
Y79 (DSMZ-ACC 246), WERI-Rb1 (DSMZ-ACC 90) and
NALM-6 (DSMZ-ACC 128), were purchased from the Ger-
man collection of microorganisms and cell cultures. The
WERI-Rb1, RBL15 and RB355 retinoblastoma cell lines and
the NALM-6 B cell leukemia cell line were lentivirally trans-
duced with green fluorescent protein (GFP)-firefly luciferase
(ffLuc)_epHIV7, and GFP-expressing cells were selected
using fluorescence-activated cell sorting (FACS). WERI-Rb1
and NALM-6 cells were maintained in RPMI 1640 (Gibco
Life technologies) supplemented with 15% heat-inactivated
fetal calf serum (FCS, Sigma-Aldrich). RBL15 and RB355 cell
lines were maintained in DMEM (Gibco Life technologies)
supplemented with 10% heat-inactivated FCS, 10 μg/ml insu-
lin (Sigma-Aldrich) and 50 μM 2-mercaptoethanol (Sigma-
Aldrich). The TMLCL EBV-transformed lymphoblastoid cell
line was maintained in RPMI 1640 supplemented with 10%
heat-inactivated FCS and 2mML-glutamine (Biochrom).
Retinoblastoma immunohistochemistry
The CD171 and CD3 (T cell marker) were immunohis-
tochemically detected in tumor sections. Primary anti-
bodies were omitted as negative controls and kidney
tissue (CD171) was used as positive control (see Add-
itional file 1: Figure S1). T cell infiltration (number of
CD3+ lymphocytes per cm2) in preserved retinoblastoma
tissue sections was quantified using the Stereo Investiga-
tor® system (MBF Bioscience). Methods of immunohisto-
chemistry are described in an additional file in more
detail (see Additional file 2).
CAR constructs
The CD171-specific CE7-CAR [36] and GD2-specific
14.2GA-CAR [37] were previously described, and were
cloned into the SIN epHIV7 lentiviral vector plasmid.
CAR lentiviruses were propagated in 293 T cells. [38]
The scFvs in both CAR constructs were codon opti-
mized and subsequently linked to a 12 (short) or 229
(long) amino acid spacer domains from the human IgG4
hinge. The long spacer domain was modified by substi-
tuting L235D and N297Q to reduce binding to the IgG
Fc gamma receptor. [39] The spacer domain connects
the antigen-binding domain to CD28 transmembrane
domain followed by the signaling module containing the
CD3zeta cytoplasmic domain and either 4-1BB or CD28.
The CAR constructs were linked downstream to a T2A
self-cleaving peptide and truncated epidermal growth
factor receptor (EGFRt) allowing CAR-T cell detection
and enrichment.
Generation and culture of CD171- and GD2-specific CAR-T
cells
Apheresis products were obtained from healthy donors
and peripheral blood mononuclear cells were isolated
using Ficoll-Paque (GE Healthcare). CD8+ T cells were
obtained by positive selection using immunomagnetic
microbeads (Miltenyi Biotec), and activated with anti-
CD3/CD28 beads (Life Technologies). On day three,
activated CD8+ T cells were transduced with the CAR
containing lentivirus. The EGFRt+ CAR-T cell subset
was enriched by immunomagnetic selection with biotin-
conjugated cetuximab (Bristol-Myers Squibb) and strep-
tavidin microbeads (Miltenyi Biotec). T cells used as
mock negative controls alongside CAR-T cells in experi-
ments were not lentivirally transduced. CAR and mock
control T cells were stimulated with irradiated periph-
eral blood mononuclear cells, irradiated TMLCL, and
OKT3 (30 ng/mL, Miltenyi Biotec), expanded according
to a rapid expansion protocol [36] and cryopreserved
until further use. Cryopreserved cells were thawed, ex-
panded as described above and functional in vitro assays
were conducted between days 11 and 16 of culture.
Functional assays
For cytokine release assays, 2 × 105 T cells were seeded
together with stimulator cells at a 2:1 effector:target
ratio. All data points were performed as technical tripli-
cates. After 24 h, supernatants were collected and stored
at − 80 °C until analysis of IFNG and IL2 using the
OptEIA™ Set (BD Biosciences) enzyme-linked immuno-
sorbent assay (ELISA) kits in accordance with the manu-
facturer’s instructions. CAR-T cell-induced cytotoxicity
was quantified in a biophotonic luciferase assay in which
the retinoblastoma cells, stably transduced with a GFP-
ffLuc_epHIV7 reporter, served as tumor target cells.
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Target cells were co-cultured in triplicate with mock-
transduced or CAR-T cells. The maximal biophotonic
luciferase signal was defined by target cells plated alone
at the same densities (RLUmax, maximal relative light
unit). After 24, 48 or 72 h, 0.14 mg D-luciferin (PerkinEl-
mer Inc.)/ml medium was added to each well, and the
biophotonic signal detected. Lysis was determined as [1-
(RLUsample/RLUmax)]× 100 in relation to untreated cells.
For sequential treatment, the additive amount of tumor
lysis was calculated related to viable tumor cells at day 3.
Flow cytometric marker and antigen detection
Cell-surface expression of GD2 (cat#565991, BD Biosci-
ences), CD8 (cat#301041, BioLegend) and CD171
(cat#130–100-691, Miltenyi Biotec) was detected by fluor-
ophore-conjugated monoclonal antibodies. EGFRt expres-
sion was detected using biotinylated cetuximab (Bristol-
Myers Squibb) and a phycoerythrin (PE)-conjugated strep-
tavidin antibody (cat#12–4317-87, BioLegend). Activation
and exhaustion were assessed by fluorophore-conjugated
monoclonal antibodies detecting CD137 (cat#309819, Bio-
Legend), CD25 (cat#302622, BioLegend), PD1 (also
known as PDCD1 or CD279, cat#329922, BioLegend),
TIM3 (cat#345006, Biolegend) and LAG3 (cat#565721,
BD Biosciences). Flow cytometry was performed on a For-
tessa X-20 (BD Biosciences) and data processed using
FlowJo software (Tree Star Inc.). Dead cells were excluded
from analyses using LIVE/DEAD™ Fixable Green Dead
Cell Stain Kit (cat#L23101, Life Technologies). Quanti-
BRITE PE calibration beads (BD Biosciences) were used to
determine GD2 and CD171 antigen density on retino-
blastoma cells according to the manufacturer’s
instructions.
Statistical analysis
To determine significance of differences in cytotoxic ac-
tivity and cytokine release of GD2-and CD171-specific
CAR-T cells compared with negative control mock T-
cells, unpaired Student’s t-test was performed using
GraphPad prism (GraphPad Software). P values < 0.05
were considered statistically significant.
Results
CD171 expressed in primary retinoblastomas and
retinoblastoma cell lines
To investigate the potential of immunotherapeutically tar-
geting retinoblastoma via the tumor antigen, CD171, we
immunohistochemically evaluated its presence and abun-
dance in 30 primary retinoblastoma samples. Tumor sam-
ples with ≥5.0% of cells expressing CD171 were
considered CD171-positive as was previously described by
Jo et al. [29] Half of the analyzed retinoblastomas (15/30)
expressed CD171 in various frequencies (Fig. 1a,
Additional file 3: Figure S2). Analysis of respective clinical
patient data confirmed that a representative patient cohort
was investigated (Table 1). Median age at diagnosis was
2.1 (range 0.12–6.5) years, and the cohort included 15
(50%) boys and 15 (50%) girls. Most tumors from this pa-
tient group were classified as ICRB group D (57%). T cell
infiltration was assessed in 6 retinoblastomas randomly
selected from our cohort of 30 retinoblastomas using im-
munohistochemical detection of the T cell marker, CD3
(Fig. 1b). All analyzed retinoblastomas were infiltrated by
T cells demonstrating potential access to retinoblastoma
for T cells, and infiltration (quantification of CD3+ cells)
ranged from 16.3 CD3+ cells/cm2 to 160.1 CD3+ cells/
cm2. We next assessed CD171 expression in 11 retino-
blastoma cell lines by flow cytometry. CD171 was
expressed on almost all cells (80–90%) in 6/11 of the ret-
inoblastoma cell lines analyzed, with 3 cell lines moder-
ately expressing CD171 (39–58%) and 2 cell lines
exhibiting low-level (< 20%) expression (Fig. 1c). We se-
lected the 3 cell lines (WERI-Rb1, RBL15 and RB355) that
most homogenously expressed CD171 for use in experi-
ments to preclinically evaluate CD171-specific CAR-T cell
therapy. To assure adequate target expression density on
these 3 cell lines, the QuantiBRITE quantification method
was applied. Highest antigen density was detected in
RB355 cells (mean = 6932 molecules/cell), with RBL15
(mean = 4988 molecules/cell) and WERI-Rb1 (mean =
2757 molecules/cell) cells with slightly lower but substan-
tial target densities (Fig. 1d). These data reveal CD171 as
possible target for retinoblastoma-specific CAR-T cell
therapy.
CD171-specific CAR-T cells target and kill retinoblastoma
cells but induce escape mechanisms
Potential CAR-T cell efficacy against the selected retino-
blastoma cell lines was assessed using in vitro assays.
We first assessed the relative ability of co-cultured ret-
inoblastoma cells to activate and induce cytokine release
by T cells harboring different CD171-specific CAR con-
structs. CD8+ bulk cells from healthy donors were lenti-
virally transduced with 4 different CAR constructs
containing either a short or long spacer domain com-
bined with either a 4-1BB or CD28 co-stimulatory do-
main (Fig. 2a). The lentiviral vector also included a
truncated EGF receptor without the signaling domain
(EGFRt), used to assess transduction efficacy. CAR-ex-
pressing cells were enriched for EGFRt expression by
immunomagnetic positive selection [27], yielding T cell
populations with 86.7–94.6% of cells expressing each
CAR construct (see Additional file 4: Figure S3A). Cyto-
kine release (IFNG and IL2) from CAR-T cells following
co-culture with WERI-Rb1, RBL15 or RB355 cell lines
was quantified by ELISA. Encounter with any of the 3
retinoblastoma cell lines induced IFNG and IL2 release
from CD171-specific CAR-T cells but not mock-
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transduced T cells used as negative controls (Fig. 2b).
Similarly, co-culture with the CD171-negative B cell
leukemia cell line, NALM-6, did not result in any cyto-
kine release, proving CAR-T cell specificity for CD171
(Additional file 5: Figure S4A + B). Activation markers
(CD25 and CD137) on T cells harboring the CD171-spe-
cific CAR constructs were also assessed by FACS ana-
lysis after retinoblastoma cell encounter. Any of the 3
retinoblastoma cells lines tested also induced both acti-
vation markers in co-cultured CD171-specific CAR-T
cells (Fig. 2c). The RBL15 cell line was more capable of
activating CAR-T cells compared to the other 2 cell
lines. Since CAR-T cell activation is regulated by both
positive and negative signals provided by the co-stimula-
tory domain, expression of the PD1, TIM3 and LAG3 in-
hibitory receptors after retinoblastoma encounter was
also assessed in FACS analyses. Co-culture with any of
the 3 retinoblastoma cell lines consistently induced
TIM3 expression in approximately half the T cell popu-
lation, while PD1 expression remained below 15% in
every case excluding an inhibitory impact on CAR-T cell
function by the PD1/PDL1-axis in our in vitro model
(Fig. 2d). Induction of LAG3 expression was moderate
and varied with retinoblastoma cell type. Our results
demonstrate that exposure to retinoblastoma cells acti-
vated CD171-specific CAR-T cells and induced cytokine
release.
Having demonstrated CAR-T cell activation after ret-
inoblastoma encounter, we investigated the ability of
CAR-T cells to kill retinoblastoma cells in a luciferase-
based reporter assay. The WERI-Rb1, RBL15 and RB355
cell lines were transduced with a GFP-firefly luciferase
reporter plasmid to support viable tumor cell quantifica-
tion. T cells harboring the various CD171-specific con-
structs were co-cultured with retinoblastoma reporter
cells in a 2:1 effector:target ratio. Cytotoxicity was
Fig. 1 CD171 is expressed in retinoblastomas and cell lines derived from retinoblastomas. a The tumor is composed of small undifferentiated, blue cells
(hematoxylin & eosin stain). Flexner-Wintersteiner rosettes may be found and are highly characteristic (arrows). The expression of CD171 was classified as
negative or positive. (Scale bar: 50 μm). b CD3+-staining is exemplarily shown for patient 1 and patient 5. CD3+ infiltration in 6 of 30 randomly chosen primary
retinoblastoma tumor samples. c CD171 cell surface expression on eleven established retinoblastoma cell lines detected with antihuman fluorochrome-
conjugated CD171 antibody (n= 3). d Number of CD171 molecules per cell calculated based on a PE-bead based assay for three selected cell lines, WERI-Rb1,
RBL15 and RB355 (mean± SD, n = 3)
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assessed following 24 h, 48 h and 72 h of co-culture by
measuring the biophotonic signal released by the
remaining viable tumor cells. CD171-specific CAR-T
cells killed significantly more retinoblastoma cells, re-
gardless of cell type, than mock-transduced negative
control T cells (Fig. 2e). There was no killing of the
CD171 negative cell line, NALM-6 (Additional file 5:
Figure S4D). Further, CD171-specific CAR-T cells
showed a dose-dependent cytotoxicity of retinoblastoma
cells. Cytotoxicity ranged from 97% with a 5:1 effector:
target ratio to 76% (1:1 effector:target ratio) to no killing
(1:10 effector:target ratio; Additional file 6: Figure S5).
These experiments demonstrate that CAR-T cells target-
ing CD171 efficiently kill retinoblastoma cells in vitro.
Since it is known that different spacers and co-stimulatory
domains have influence on the performance of CAR-T cells
we compared the T cells harboring different CAR con-
structs in terms of cytokine release, activation, expression of
inhibitory receptors and killing. T cells harboring the
CD171 CAR construct with the long spacer and CD28 co-
stimulatory domain (CD171-long-CD28) released the most
IFNG and IL2 after encounters with any tested cell line (Fig.
2b), although differences did not reach any statistically sig-
nificance. All CAR-T cells were comparably well activated
following co-culture with WERI-Rb1, RBL15 or RB355 cell
lines, except T cells harboring the CD171-short-4-1BB con-
struct which displayed the lowest levels of both markers
(Fig. 2c). Co-culture with any of the 3 retinoblastoma cell
lines consistently induced TIM3 expression, regardless of
the CD171-specific CAR construct type expressed (Fig. 2d).
The CAR construct used did not have as large an impact on
the CAR-T cell ability to kill retinoblastoma cells as it had
on the cytokine release by the co-cultured CAR-T cells.
Most CD171-specific CAR-T cells were able to kill nearly
100% (Fig. 2e) of the retinoblastoma cells underling the po-
tency of CAR-T cell therapy against retinoblastoma. As
already described by Long et al., the ability of CAR-T cells
to produce polyfunctional cytokines in response to antigen
encounter is a better predictor of CAR-T cell antitumor effi-
cacy in vivo than cytolytic efficacy alone. [40] Since the
CAR construct utilizing the long spacer and CD28 co-
stimulatory domains produced slightly higher amounts of
IFNG and IL2 in vitro, it was selected for the remaining
experiments.
Tumor cells use different strategies to escape attacks
from the immune system. One strategy is to downregu-
late the antigens being targeted by host T cells or the
engineered CAR-T cells. [41] To explore whether retino-
blastoma cells were utilizing this strategy, we investi-
gated CD171 expression on WERI-Rb1 and RB355 cells
via FACS analysis at several time points after transient
co-culture with CD171-specific CAR-T cells (Fig. 3a).
Transient encounter with CD171-specific CAR-T cells
initially reduced CD171 expression on WERI-Rb1 and
RB355 cells by 11.4- and 12.3-fold, respectively when
assessed on day 3 concomitantly with CAR-T cell re-
moval (Fig. 3b, Additional file 7: Figure S6). However,
CD171 expression returned on retinoblastoma cells by
day 10, with antigen levels comparable to untreated cells,
and remained at these levels on day 14. The differentially
regulated antigen expression indicates the potential im-
mune evasion of retinoblastoma cell lines after CAR-T
cell encounter revealing the need of targeting more than
1 antigen.
Table 1 Patient and tumor characteristics included in primary retinoblastoma cohort
Patients Total CD171 positive* CD171 negative
N (%) 30 (100) 15 (50) 15 (50)
Minimum age at diagnosis (years) 0.1 0.4 0.1
Maximum age at diagnosis (years) 6.5 6.4 6.5
Median age at diagnosis (years) 2.1 (0.12–6.5) 1.8 2.1
Sex (%) ♀: 15 (50) ♀:9 (60) ♀:6 (40)
♂: 15 (50) ♂:6 (40) ♂:9 (60)
Unilateral (%) 23 (77) 12 (80) 11 (73)
Bilateral (%) 7 (23) 3 (20) 4 (27)
ICRB (%)
A 0 (0) 0 (0) 0 (0)
B 0 (0) 0 (0) 0 (0)
C 1 (3) 1 (7) 0 (0)
D 17 (57) 9 (60) 7 (47)
E 7 (20) 3 (20) 4 (26)
n.a. 6 (20) 2 (13) 4 (26)
* ≥ 5% CD171 positive cells, N = number, ICRB = International Classification of Retinoblastoma
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Fig. 2 (See legend on next page.)
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GD2 is a second promising target for CAR-T cell therapy
in retinoblastoma
We explored whether GD2 could be effective as a
second target in retinoblastoma cells in our in vitro
testing pipeline. GD2 is known to be expressed on
neuroectodermal tumors [22] and is, besides IL13RA2
and mesothelin, one of the few CAR-T cell targets to
have produced solid tumor regression. [42–44] Since
our sample cohort used to assess CD171 was long-
term stored, formalin-fixed and paraffin embedded
material it was inappropriate for GD2 immunohisto-
chemistry. However, it has previously been shown
that retinoblastoma derived metastases in patients
express high GD2 levels even at the time of minimal
residual disease after retinoblastoma therapy is com-
pleted. [19, 20] We think it is highly unlikely that
GD2 is not frequently expressed in retinoblastoma,
and therefore, it is a suitable target for CAR-T cell
therapy. Further, flow cytometry analysis of our ret-
inoblastoma cell line panel revealed that all cell lines
expressed GD2 (Fig. 4a). More than 90% of cells
expressed GD2 in 6 of the 11 cell lines, including
WERI-Rb1 and RBL15 (96.0–99.9%), while approxi-
mately half the cells expressed GD2 in 4 of 11 cell
lines, including RB355 (mean = 52.9%, range = 41–
65%). Investigating the number of GD2 antigen-
(See figure on previous page.)
Fig. 2 CD171-specific CAR-T cells recognize and kill retinoblastoma cell lines in vitro. a Scheme of CD171-specific 2nd generation CAR variants
displaying color-coding of the different constructs used. b IFNG and IL2 release of CAR-T cells following a co-culture at a 2:1 effector:target (E:T)
ratio with retinoblastoma cell lines (mean ± SD, n = 3). Cell surface expression of activation markers CD137 and CD25 c and inhibitory receptors
LAG3, PD1 and TIM3 (d) on CAR-T cells following a 24-h tumor co-culture at a 2:1 E:T ratio (mean ± SD, n = 3). Color-coding is the same as used
in B. e Cytotoxicity of CD171-specific CAR-T cells is determined by luciferase-based killing assay following a tumor co-culture for 24, 48 and 72 h
at a 2:1 E:T ratio (mean ± SD, n = 3). Color-coding is the same as used in B. * p≤ 0.5; **, p≤ 0.01
Fig. 3 CD171-specific CAR-T cell treatment leads to transient antigen loss. a Scheme of the experimental process. Time-dependent cell surface
expression of CD171 on WERI-Rb1 (b) and RB355 cells (c) following 3-day co-culture with CD28-long spacer CAR-T cells and on day 10 and 14
after CAR-T cells removal (mean ± SD, n = 3)
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binding sites per cell showed that WERI-Rb1 and
RBL15 cells provided > 80,000 target molecules per
cell, with respective ranges of 136,412 – 146,692.0
and 62,770–100,846 targets/cell (Fig. 4b). Consistent
with the lower GD2 expression measured in the
RB355 cell line, only 3778–4775 target molecules per
cell were detected. Even with the lower GD2 expres-
sion in some retinoblastoma cell lines, these data
support GD2 as potential second target for retino-
blastoma-specific CAR-T cell therapy.
To investigate the potential efficacy of GD2-specific
CAR-T cells against retinoblastoma cells, we generated
CAR-T cells targeting the 14.2GA-GD2 epitope with the
same four different CAR constructs used in the CD171-
specific CAR-T cells (see Additional file 4: Figure S3B).
We again used the WERI-Rb1, RBL15 and RB355 cell
lines in co-culture with GD2-specific CAR-T cells before
investigating T cell activation and tumor cell killing effi-
cacy in vitro. Similar to CD171-specific CAR-T cells, en-
counter with WERI-Rb1 and RBL15 induced IFNG and
IL2 release from GD2-specific CAR-T cells but not
mock-transduced T cells used as negative controls
(Fig. 5a). Co-culture with the GD2-negative NALM-6
cell line served as control for antigen-specificity of GD2-
specific CAR-T cells (Additional file 5: Figure S4C + D).
In concordance with the low antigen levels detected by
flow cytometry analysis, encounter with RB355 induced
neither IFNG nor IL2 release from GD2-specific CAR-T
cells. Activation markers (CD25 and CD137) on T cells
harboring the GD2-specific CAR constructs were also
assessed by flow cytometry analysis after retinoblastoma
encounter. Any of the 3 retinoblastoma cell lines tested
induced both activation markers in co-cultured GD2-
specific CAR-T cells (Fig. 5b). The WERI-Rb1 and
RBL15 cell lines were more capable of activating CAR-T
cells than the RB355 cell line, in line with its lower tar-
get expression. Expression of activation markers on
GD2-specific CAR-T cells was stronger increased upon
encounter with WERI-Rb15 and RBL15 cells than on
CD171-specific CAR-T cells. Co-culture with WERI-Rb1
induced a 3-fold higher CD25 (range = 2.3-fold-4.8-fold)
and 1.9-fold higher CD137 (range = 1.5-fold-3.1-fold) ex-
pression on GD2-specific CAR-T cells in comparison to
CD171-specific CAR-T cells, while co-culture with
RBL15 cells induced a 1.3-fold higher (range = equal ex-
pression-1.8-fold) and 1.3-fold higher CD137 (range =
equal-expression-1.8-fold) expression of activation
markers. Expression of the LAG3, TIM3 and PD1 inhibi-
tory receptors were also assessed after retinoblastoma
encounter by flow cytometry analysis. Co-culture with
any of the 3 retinoblastoma cell lines more strongly in-
duced expression of all 3 inhibitory receptors in most
GD2-specific CAR-T cells than was observed in CD171-
specific CAR-T cells (Fig. 5c). Encounter with WERI-
Rb1 induced 3.6-fold higher LAG3 expression in GD2-
specific compared to CD171-specific CAR-T cells,
whereas RBL15 encounter induced 1.6-fold higher LAG3
expression. Interestingly, within GD2-specific CAR-T
cells, PD1 expression on CAR-T cells harboring the
CD28 co-stimulatory domain was 2.2-fold (WERI-Rb1),
2.5-fold (RBL15) and 1.5-fold (RB355) higher compared
to CAR-T cells with 4-1BB co-stimulation domain. Our
results demonstrate that exposure to retinoblastoma
cells activated GD2-specific CAR-T cells and induced
cytokine release, dependent on antigen density.
To test the ability of GD2-specific CAR-T cells to kill
retinoblastoma cells in vitro, we assessed cytotoxic effi-
cacy using the luciferase-based reporter assay. GD2-spe-
cific CAR-T cells were co-cultured in a 2:1 effector:
target ratio with retinoblastoma reporter cells before
Fig. 4 GD2 is expressed on retinoblastoma cell lines. a GD2 cell surface expression on eleven established retinoblastoma cell lines detected with
antihuman fluorochrome-conjugated GD2 antibody. b Number of GD2 molecules per cell calculated based on a PE-bead based assay for 3 selected
cell lines, WERI-Rb1, RBL15 and RB355 (mean ± SD, n = 3)
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assessing the biophotonic signal released by the
remaining viable tumor cells after 24 h, 48 h and 72 h.
GD2-specific CAR-T cells killed significantly more
WERI-Rb1 and RBL15 cells than the mock-transduced
negative control (Fig. 5d). Cytotoxicity against RB355
cells was weaker, in line with the lower target expres-
sion. The GD2-negative NALM-6 cell line was not killed
by GD2-specific CAR-T cells (Additional file 5: Figure
S4D). Dose-dependent cytotoxicity of GD2-specific
CAR-T cells was demonstrated in co-culture with
RBL15 cells in different effector:target ratios. Cytotox-
icity ranged from 90.1% in a 5:1 effector:target ratio to
66% (1:1 effector:target ratio) to 1.5% (1:10 effector:tar-
get ratio; Additional file 6: Figure S5). These experi-
ments demonstrate that CAR-T cells targeting GD2
efficiently kill retinoblastoma cells in vitro in an antigen
density-dependent manner.
The impact of different spacer and co-stimulatory do-
mains on cytokine release, activation, inhibitory receptor
expression and killing ability of T cells targeting GD2 was
also assessed. Similar to CD171-specific CAR-T cells, T
cells harboring the long spacer and CD28 co-stimulatory
domain released more IFNG and IL2 after encounters of
any tested cell line than T cells harboring the short spacer
and CD28 co-stimulatory domain (Fig. 5a), indicating su-
perior effector functionality of T cells equipped with the
GD2-long-CD28 construct. T cells harboring the long spa-
cer with either co-stimulatory domain released compar-
able amounts of IL2 after encounters with WERI-Rb1 and
RBL15. T cells harboring all constructs except the GD2-
short-CD28 CAR construct were comparably well acti-
vated by WERI-Rb1 or RBL15 cell co-culture (Fig. 5b). In-
hibitory receptor expression was comparably induced in T
cells harboring all constructs, except that PD1 expression
was stronger in T cells harboring the CD28 co-stimulatory
domain (Fig. 5c). The CAR construct used did not have as
large an impact on the CAR-T cell ability to kill retino-
blastoma cells as it had on cytokine release by the T cells.
Most GD2-specific CAR-T cells were able to kill nearly
90% (Fig. 5d) of the retinoblastoma cells underlining the
potency of GD2-specific CAR-T cell therapy against ret-
inoblastoma. Although the CAR construct had less impact
on efficacy of GD2-specifc compared with CD171-specific
CAR-T cells, the GD2-long-CD28 construct performed
best in vitro and was selected for the remaining
experiments.
Having verified cytokine release, activation and cytolytic
capacity we also assessed tumor escape mechanisms of
retinoblastoma cell lines following GD2-specific CAR-T
cell encounter. As done before for the CD171-specific
CAR-T cells, we investigated GD2 expression on WERI-
Rb1 and RB355 cells via FACS analysis at several time
points after transient co-culture with GD2-specific CAR-T
cells (Fig. 5e, Additional file 8: Figure S7). Interestingly,
while transient encounter with GD2-specific CAR-T cells
downregulated the already low GD2 expression on RB355
cells by more than half when assessed on day 3 concomi-
tantly with CAR-T cell removal, WERI-Rb1 cell lines did
not change GD2 expression. RB355 cells regained GD2
expression by day 14, with antigen levels comparable to
untreated cells. GD2 antigen expression may only be dif-
ferentially regulated in cells with low antigen densities, re-
ducing the risk of potential immune evasion when GD2 is
targeted in retinoblastoma cells.
Sequential CAR-T cell treatment counteracts antigen loss
and improves cytotoxicity against retinoblastoma cells
We investigated whether sequentially treating retino-
blastoma cells with CAR-T cells targeting the same or
different target antigens could reduce escape via CD171
or GD2 downregulation on retinoblastoma cells. All 11
retinoblastoma cell lines showed CD171+GD2+-positive
cells as analyzed by flow cytometry (range = 11–96%,
Additional file 9: Figure S8). T cells harboring CD171-
or GD2-specific constructs with the long spacer and
CD28 co-stimulatory domains were used, since these
performed best in single-treatment experiments. CAR-T
cells targeting either CD171 (treatment 1) or GD2 (treat-
ment 2) were co-cultured with retinoblastoma cells in a
1:5 effector:target ratio for 3d before examining CD171
and GD2 expression on tumor cells (Fig. 6a). CAR-T
cells were removed on day 3 and replaced with CAR-T
cells targeting either the same or the alternate antigen.
CD171 and GD2 expression was measured again on day
6. Sequential treatment initiated with CD171-specific
CAR-T cells (treatment 1) reduced CD171 expression
on WERI-Rb1 cells to 29.3% on day 3, and further re-
duced CD171 expression to only < 12% of cells on day 6
regardless of whether CAR-T cells targeting CD171 or
GD2 were applied on day 3 (Fig. 6b). Initiating sequen-
tial treatment with GD2-specific CAR-T cells (treatment
2) did not downregulate CD171 expression on WERI-
(See figure on previous page.)
Fig. 5 GD2-specific CAR-T cells kill retinoblastoma cells in vitro without causing antigen loss in WERI-Rb1. a IFNG and IL2 release of CAR-T cells following a
24-h co-culture at a 2:1 E:T ratio with retinoblastoma cell lines (mean ± SD, n = 3). Cell surface expression of activation markers CD137 and CD25 (b) and
inhibitory receptors LAG3, PD1 and TIM3 (c) on CAR-T cells is shown upon a 24-h co-culture at a 2:1 E:T ratio (mean ± SD, n = 3). Color-coding is the same
as used in a. d Cytotoxicity of GD2-specific CAR-T cells is displayed in comparison to mock-transduced T cells. Cytotoxicity was measured by a luciferase-
based killing assay following a 24, 48 and 72 h co-culture at a 2:1 E:T ratio (mean ± SD, n = 3). Color-coding is the same as used in a. e Cell line-dependent
loss of GD2 cell surface expression is shown after a 72-h co-culture as well as day 10 and 14 after CAR-T cell removal (n = 3). *, p≤ 0.5; **, p≤ 0.01
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Rb1 cells on day 3, but reduced WERI-Rb1 cells express-
ing CD171 to 27.4% on day 6 if GD2-specific CAR-T
cells were re-applied and to 12.5% if CD171-specific
CAR-T cells were applied at day 3. GD2 expression on
WERI-Rb1 cells remained unaffected on day 3, regard-
less of the antigen being targeted (treatment 1 or 2), but
treatment on day 3 with either CD171- or GD2-specific
CAR-T cells downregulated GD2 expression on WERI-
Rb1 cells to similar levels. Exposing RB355 cells to
CD171-specific CAR-T cells (treatment 1) reduced
CD171 and GD2 expression to < 8% of the cells by day 3
(Fig. 6c). The very low levels of target expression at day
3, made accurate assessment of further target reduction
on day 6 difficult. Interestingly, GD2 expression levels
on RB355 cells were more strongly reduced on day 3 by
CAR-T cells targeting CD171 than GD2, indicating re-
duction of antigen expression was independent of the
CAR target. Sequentially applied GD2-specific CAR-T
cells (treatment 2) barely influenced CD171 expression
on RB355 cells on days 3 or 6, and only strongly reduced
expression of either target if treated with CD171-specific
CAR-T cells on day 3. Our data demonstrate that anti-
gen downregulation is triggered by CAR-T cell exposure,
but that downregulation does not always depend on the
antigen targeted by the CAR.
In parallel, we assessed cytotoxic efficacy of sequential
CAR-T cell treatment targeting the same or 2 different
antigens using the same luciferase-based reporter assay
for tumor cell killing as in our monotreatment experi-
ments. The same treatment regimens (Fig. 6a) were con-
ducted with 1:5 effector:target ratios for CAR-T cells
and WERI-Rb1 or RB355 cells (Fig. 6d). CD171- and
GD2-specific CAR-T cells showed comparable killing ef-
ficacy of WERI-Rb1 cells during treatment 1 and 2.
Switching from GD2- to CD171-specific CAR-T cells in-
creased tumor cell lyses by 30% from day 3 to day 6
while a sequential treatment with GD2-specfifc CAR-T
cells showed an increase of tumor lysis of only 19% indi-
cating a benefit for administration of sequential CAR-T
cell therapy targeting different antigens. Analyzing
CD171- and GD2-specific CAR-T cell killing ability of
RB355 cells revealed higher cytotoxicity of CD171- than
of GD2-specific CAR-T cells during treatment 1 and 2.
Treatment with GD2-specific CAR-T cells followed by
subsequent CD171-specific CAR-T cell treatment dis-
played a significantly higher tumor lysis compared to a
second GD2-specific CAR-T cell treatment. Our in vitro
analyses support that sequentially targeting multiple an-
tigens with CAR-T cells increases treatment efficacy,
with the greatest benefit produced by targeting CD171
before GD2, even in cells with initial low-density GD2
expression.
Discussion
We present preclinical evidence that CAR-T cell therapy
targeting retinoblastoma-specific antigens could be a
promising option to treat both primary tumors as well
as metastasized or metastasizing malignant cells.
CD171- and GD2-specific CAR-T cells were strongly
activated by retinoblastoma cell encounter and demon-
strated potent killing efficacy of retinoblastoma cells in
vitro dependent on target antigen expression. Though all
tested CAR constructs demonstrated equal activation
and killing ability for either target, the CAR construct
harboring the long extracellular spacer in combination
with the CD28 co-stimulatory domain, tended to release
higher amounts of effector cytokines, although this dif-
ference did not reach statistical significance While
CD171 expression was completely lost on all cell lines
following CAR-T cell treatment, GD2 was only down-
regulated in cell lines initially harboring low GD2 levels.
Here, we reveal enhanced retinoblastoma cell killing in
alternating the CAR-T cell killing in sequential CAR-T
cell challenges.
Watanabe et al. previously demonstrated for CD20-
specific CAR-T cells that antigen density on acute
lymphatic leukemia cell lines influenced CAR-T cell effi-
cacy. [45] The same was shown by Fry et al. in patients
with CD22-diminished or -negative leukemia blasts, who
did not respond to CD22-specific CAR-T cell therapy.
[46] Turrati et al. developed a cellular model where
HER2 antigen expression could be increased, which
caused enhanced CAR-T cell activity. [47] Here, we also
show antigen expression level was correlated with cyto-
toxicity for GD2-specific CAR-T cells, since low GD2-
expressing RB355 cells were only marginally killed, while
WERI-Rb1 cells with higher GD2 expression elicited effi-
cient killing.
The non-signaling extracellular spacer plays a pivotal
role in tumor recognition: as each new scFv and target
molecule on tumor membrane define a distinct biophys-
ical synapse, a unique adjustment is needed for every
(See figure on previous page.)
Fig. 6 Sequential targeting of different antigens increases CAR-T cell efficacy in vitro. a Scheme of the experimental setting depicting treatment
option I and II. b CD171 and GD2 cell surface expression on WERI-Rb1 cell line is shown on day 3 and 6 after treatment. Retinoblastoma cells
were initially treated on day 0 and sequential treatment was conducted on day 3 at a 1:5 E:T ratio, respectively (mean ± SD, n = 3). C. For cell line
RB355, CD171 and GD2 expression is illustrated as in b (n = 3). d Lysis of WERI-RB1 and RB335 is shown after initial treatment with CD171- or
GD2-specific CAR-T cells and on day 3 and after sequential treatment on day 6 (1:5 E:T ratio, n = 3). Mock-transduced T cells serve as negative
control. Treatment is specified in the table below. *, p≤ 0.5; **, p ≤ 0.01
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target antigen. Hudecek et al. could previously demon-
strate that T cells harboring a short spacer-containing
CD19-CAR were able to eradicate tumor cells in vivo
while the same dose of CD19-specific CAR-T cells with
a long spacer failed to do so. [15] We previously showed
that levels of activation and cytotoxicity for CD171-spe-
cific CARs varied depending on the extracellular spacer
length when targeting neuroblastoma. [36] In this previ-
ous study, we compared CD171-specific CAR constructs
that all harbored the 4-1BB co-stimulatory domain but
different spacer length. The CAR construct with the long
spacer domain performed best in in vitro assays, but,
interestingly, the superiority of the long spacer CAR was
reversed in vivo, most likely due to activation-induced
cell death caused by recursive antigen exposure. The
data we present here showed no clear superiority for any
of the extracellular spacer length, irrespectively of target
cell line or amount of antigen expression. However, in-
vestigation of the different CAR constructs in preclinical
mouse models might reveal differences, since CAR-T
cell performance has been shown to be influenced by
additional factors such as CAR-T cell expansion and
persistence in vivo. [48] The mechanisms by which dif-
ferent co-stimulatory domains influence T cell expan-
sion, function and persistence are not yet fully
understood, but the CD28 co-stimulatory domain is as-
sociated with enhanced anti-tumor efficacy and T cell
functionality and enhanced T cell survival and persist-
ence is attributed to the 4-1BB co-stimulatory domain.
[49] Hudecek et al. revealed higher cytokine release for
ROR1-specific CAR-T cells harboring a CD28 co-stimu-
latory domain compared to T cells with a 4-1BB co-
stimulatory domain. [50] Long et al. previously showed
that tonic signaling in CAR-T cells harboring a CD28
co-stimulatory domain led to T cell exhaustion and re-
duced functionality in vivo, which could be ameliorated
by incorporation of 4-1BB into GD2-CAR-T cells. [40]
In line with these findings, our data depicts increased
PD1 expression on GD2-specific CAR-T cells harboring
the CD28 co-stimulatory. However, from our functional
analyses of GD2- and CD171-specific CAR-T cells, we
conclude that all tested CD171- and GD2-specific CAR
constructs, irrespective of the co-stimulatory domain,
against retinoblastoma in vitro. Further testing in pre-
clinical mouse models will reveal whether there is a
ranking between CD171- and GD2-specific CARs
equipped with 4-1BB or CD28 costimulatory domains
against retinoblastoma.
Differences in CAR-T cell exhaustion of CAR-T cells
with different scFvs were previously demonstrated by
Yin et al., who analyzed EGFRvIII- and IL-13Rα2-target-
ing CAR-T cells against the same tumor model. [51] By
using different scFvs, Yin et al. showed a higher expres-
sion of the immune checkpoint molecule CTLA-4 in
higher stimulated CAR-T cells, while TIM-3 and PD1
are predominantly expressed on less activated CAR-T
cells. [51] In our study, the differences between the ex-
pression of inhibitory receptors could also be explained
by the different scFvs used. Further, the activation level
is not significantly higher but a trend towards higher
cytokine production and expression of activation
markers can be observed after 24 h of co-culture and
may reach significant difference after 48 h.
On the way to translate these findings into the clinic,
in vivo experiments need to further explore potential
toxicities, e.g. cytokine release syndrome, in context of
an ocular tumor.
In general, tumor cells are capable of evading targeted
immune therapy by downregulating the targeted antigen
leading to reduced tumor recognition and rendering
CAR-T cell therapy inefficient. [42, 52] Clinical applica-
tion of sequential lymphoma-specific CAR-T cells was
recently described by Shalabi et al. [53] Targeting B-cell
malignancies with CD19-specific CAR-T cells resulted in
outgrowth of antigen-negative variants. However, subse-
quent targeting with a second CAR-specificity could
achieve cancer regression and prolonged survival of can-
cer patients, highlighting the importance of sequential
tissue evaluation through the course of treatment. Fry et
al. revealed CD22-specific CAR-T cell therapy is an op-
tion for patients relapsing after CD19-directed treat-
ment. [46] Brown et al. demonstrated a response in a
patient with recurrent multifocal glioblastoma using se-
quentially administered CAR-T cells having the same
target specificity. [44] While loss of both antigens was
observed in RB355 cell lines, the WERI-Rb1 cell line did
not downregulate GD2 levels independently of CAR spe-
cificity. The different expression pattern could be related
to differences in GD2 expression between the cell lines.
As RB355 cells generally express low levels of GD2 and
RB355 cells express fewer antigen molecules per cell, the
downregulation may be detected earlier than in the high
GD2 expression background on WERI-Rb1 cells. The
subsequent GD2 upregulation after 10 days may be due
to an indispensable GD2 function in the cell population.
GD2 is associated with tumorigenesis as well as cancer
cell proliferation and invasion. [24] Here we demonstrate
that sequentially administering CAR-T cells targeting
different antigens achieves higher CAR-T cell killing
ability.
Conclusions
Our data revealed CD171 and GD2 as effective targets
for CAR-T cell therapy for retinoblastoma in vitro. We
demonstrated the risk potential of antigen loss on tar-
geted tumor cells after CAR-T cell treatment, but also
show that sequentially switching antigen specificity in
the CAR-T cell therapy provides a striking benefit for
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retinoblastoma cell killing ability. This work provides the
basis for in vivo testing to select the most beneficial regi-
mens and target combinations on the way to establishing
CAR-T cell therapy for retinoblastoma.
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